Home health and hospice: what US businesses sold for
What is my home health and hospice business worth?
Home health and hospice businesses in the United States sold for a median of 11.5 times EBITDA (10+ deals under US$2 billion, deals announced 2010 to 2021, every year we hold). The middle half of those deals ran from 10.5 to 12.5 times.
Deals updated October 2026
Part of Health care and social assistance.
By deal size
Each size band on its own. A band with too few deals shows no figure.
US$10 million to US$500 million
We hold too few deals in this group and size to give a figure.
US$500 million to US$2 billion
We hold too few deals in this group and size to give a figure.
All deals
Median 12.5 times EBITDA. The middle half of deals ran from 11.5 to 14.5 times (10+ deals of all sizes, deals announced 2017 to 2023, the last ten years).
Pick an industry and a size. Enter your yearly earnings to see them at the multiples those businesses sold at. Nothing you enter leaves this page.
This is not a valuation. It is arithmetic on reported deals. A buyer sets the price after testing your earnings, customers and plan.
Home health and hospice: too few deals to show a figure
We hold fewer than five US deals in Home health and hospice at this size. That is too few to show a figure.
The nearest group with enough deals is Health care and social assistance. Its figures are below.
Shown in its place: Health care and social assistance
Health care and social assistance: what buyers paid
In Health care and social assistance, US deals in our database sold at a median of 9.0 times EBITDA. The middle half sold at 7.5 to 11.5 times.
30+ deals, announced 2005 to 2023. Too few recent deals sit in this group, so it covers every year from 2005.
These are US deals in our database with a published value. Most come from bankers' opinions filed with US mergers, so they lean to larger businesses.
How these figures are made. Where these deals come from, and what they leave out, is on the method page.
These are US deals in our database with a published value. Most come from bankers' opinions filed with US mergers, so they lean to larger businesses.
Built by Andrew Wilson and Claire Grego, former partners of strategy consulting firms. Between them they have worked at Bain, BCG, Monitor Deloitte and Strategy&.